Logo wahanariau.com
  2. Adagene

Adagene

Index
Globenewswire

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

Sabtu, 18 April 2026 - 22:45:02 Wib
Globenewswire

Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board

Selasa, 14 April 2026 - 21:10:22 Wib
Globenewswire

Freshworks Expands IT Asset Management Capabilities by Adding Continuous Infrastructure Discovery and Dependency Mapping to Freshservice

Kamis, 02 April 2026 - 22:18:42 Wib
Globenewswire

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

Kamis, 02 April 2026 - 22:17:51 Wib
Globenewswire

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Kamis, 02 April 2026 - 22:17:14 Wib
Globenewswire

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Kamis, 02 April 2026 - 22:16:27 Wib
Globenewswire

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

Kamis, 02 April 2026 - 22:05:29 Wib
Globenewswire

Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

Rabu, 18 Maret 2026 - 04:56:06 Wib
Globenewswire

Adagene to Participate in Two Upcoming Investor Conferences

Kamis, 19 Februari 2026 - 20:20:12 Wib
Globenewswire

Adagene Provides Business Update and 2026 Objectives

Jumat, 23 Januari 2026 - 20:33:21 Wib
Globenewswire

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

Rabu, 17 Desember 2025 - 07:01:21 Wib
Globenewswire

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Kamis, 13 November 2025 - 23:24:02 Wib
Globenewswire

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

Sabtu, 01 November 2025 - 01:03:57 Wib
Globenewswire

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

Selasa, 16 September 2025 - 19:30:00 Wib
Globenewswire

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

Jumat, 05 September 2025 - 20:47:22 Wib
Globenewswire

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

Rabu, 03 September 2025 - 23:38:04 Wib
Globenewswire

Adagene to Participate in Two Investor Conferences in September

Selasa, 26 Agustus 2025 - 23:06:44 Wib
Globenewswire

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

Rabu, 13 Agustus 2025 - 19:55:00 Wib
Globenewswire

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

Rabu, 16 Juli 2025 - 01:27:26 Wib
Globenewswire

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Selasa, 08 Juli 2025 - 21:59:29 Wib
Globenewswire

Adagene Announces up to $25 Million Strategic Investment from Sanofi

Selasa, 01 Juli 2025 - 18:30:00 Wib
Globenewswire

Adagene to Present at Jefferies Global Healthcare Conference 2025

Selasa, 27 Mei 2025 - 19:00:00 Wib
Globenewswire

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Jumat, 23 Mei 2025 - 21:30:35 Wib
Globenewswire

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

Selasa, 29 April 2025 - 03:05:45 Wib
Globenewswire

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

Rabu, 23 April 2025 - 21:22:05 Wib